Michael Grundman

24.9k total citations · 10 hit papers
115 papers, 14.8k citations indexed

About

Michael Grundman is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Michael Grundman has authored 115 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Physiology, 48 papers in Psychiatry and Mental health and 19 papers in Molecular Biology. Recurrent topics in Michael Grundman's work include Alzheimer's disease research and treatments (52 papers), Dementia and Cognitive Impairment Research (45 papers) and Cholinesterase and Neurodegenerative Diseases (18 papers). Michael Grundman is often cited by papers focused on Alzheimer's disease research and treatments (52 papers), Dementia and Cognitive Impairment Research (45 papers) and Cholinesterase and Neurodegenerative Diseases (18 papers). Michael Grundman collaborates with scholars based in United States, United Kingdom and Canada. Michael Grundman's co-authors include Mary Sano, Leon J. Thal, Ronald G. Thomas, Steven H. Ferris, Eric Pfeiffer, Kimberly Schafer, Shelia Jin, Rachelle S. Doody, Carl W. Cotman and Christopher Ernesto and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Medicine.

In The Last Decade

Michael Grundman

112 papers receiving 14.2k citations

Hit Papers

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Bo... 1997 2026 2006 2016 1997 2005 1997 2004 2003 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
    1997 1.8k citations Mary Sano, Christopher Ernesto et al. profile →
  2. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
    2005 1.3k citations Ronald G. Thomas, Michael Grundman et al. profile →
  3. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
    1997 953 citations Mary Sano, Michael Grundman et al. Alzheimer Disease & Associated Disorders profile →
  4. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials
    2004 764 citations Michael Grundman Archives of Neurology profile →
  5. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    2003 744 citations Kimberly Schafer, Michael Grundman et al. profile →
  6. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
    2000 736 citations Ruth A. Mulnard, Carl W. Cotman et al. profile →
  7. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
    2011 554 citations Reisa A. Sperling, Clifford R. Jack et al. Alzheimer s & Dementia profile →
  8. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
    2010 536 citations Juha O. Rinne, David J. Brooks et al. The Lancet Neurology profile →
  9. Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change
    1997 528 citations Lara Schneider, Jason T. Olin et al. Alzheimer Disease & Associated Disorders profile →
  10. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
    2020 208 citations Kaj Blennow, Steven T. DeKosky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Grundman United States 48 7.0k 5.9k 2.6k 2.4k 2.0k 115 14.8k
Ronald G. Thomas United States 60 7.7k 1.1× 5.6k 0.9× 3.0k 1.1× 2.1k 0.9× 2.7k 1.4× 179 18.7k
Pierre N. Tariot United States 62 5.1k 0.7× 7.7k 1.3× 3.9k 1.5× 1.7k 0.7× 1.8k 0.9× 287 14.9k
Stephen Salloway United States 48 5.9k 0.8× 5.1k 0.9× 2.1k 0.8× 2.8k 1.2× 2.0k 1.0× 180 13.9k
Eric Siemers United States 45 7.2k 1.0× 4.5k 0.8× 2.1k 0.8× 1.7k 0.7× 2.6k 1.3× 167 12.0k
John C.S. Breitner United States 78 8.1k 1.2× 9.4k 1.6× 2.0k 0.7× 3.3k 1.4× 2.4k 1.2× 279 21.2k
Paul Aisen United States 63 8.2k 1.2× 8.3k 1.4× 1.8k 0.7× 2.6k 1.1× 2.3k 1.2× 275 17.1k
Lon S. Schneider United States 58 3.7k 0.5× 7.6k 1.3× 3.1k 1.2× 1.9k 0.8× 1.4k 0.7× 267 15.1k
Francesco Panza Italy 67 6.6k 0.9× 3.6k 0.6× 1.5k 0.6× 1.8k 0.7× 2.0k 1.0× 368 15.2k
Miia Kivipelto Sweden 80 10.2k 1.5× 9.8k 1.7× 1.8k 0.7× 3.3k 1.4× 3.2k 1.6× 434 26.7k
Rachelle S. Doody United States 55 8.5k 1.2× 10.2k 1.7× 4.3k 1.6× 3.2k 1.3× 2.6k 1.3× 243 21.3k

Countries citing papers authored by Michael Grundman

Since Specialization
Citations

This map shows the geographic impact of Michael Grundman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Grundman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Grundman more than expected).

Fields of papers citing papers by Michael Grundman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Grundman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Grundman. The network helps show where Michael Grundman may publish in the future.

Co-authorship network of co-authors of Michael Grundman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Grundman. A scholar is included among the top collaborators of Michael Grundman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Grundman. Michael Grundman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brangman, Sharon A., Jacobo Mintzer, Michael Grundman, et al.. (2024). Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease. EClinicalMedicine. 73. 102693–102693. 5 indexed citations
2.
Vijverberg, Everard G.B., Willem de Haan, Stefania Catalano, et al.. (2024). A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(6). 1809–1817. 6 indexed citations
3.
Aigbogun, Myrlene Sanon, Martin Cloutier, Marjolaine Gauthier‐Loiselle, et al.. (2020). Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. Journal of Alzheimer s Disease. 77(3). 1181–1194. 16 indexed citations
4.
Pontecorvo, Michael J., Andrew Siderowf, Bruno Dubois, et al.. (2017). Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders. 44(3-4). 129–143. 32 indexed citations
5.
Cedarbaum, Jesse M., Mark Jaros, C. Hernandez, et al.. (2012). Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimer s & Dementia. 9(1S). S45–55. 95 indexed citations
6.
Grundman, Michael, Michael J. Pontecorvo, Stephen Salloway, et al.. (2012). Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Disease & Associated Disorders. 27(1). 4–15. 93 indexed citations
7.
Sperling, Reisa A., Clifford R. Jack, Sandra E. Black, et al.. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer s & Dementia. 7(4). 367–385. 554 indexed citations breakdown →
8.
Rinne, Juha O., David J. Brooks, Martin N. Rossor, et al.. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. 9(4). 363–372. 536 indexed citations breakdown →
9.
Harrison, John, Sonia L. Minassian, Lisa Jenkins, et al.. (2007). A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials. Archives of Neurology. 64(9). 1323–1323. 156 indexed citations
10.
Grundman, Michael. (2004). Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. Archives of Neurology. 61(1). 59–59. 764 indexed citations breakdown →
11.
Pasquier, Florence, Toshiya Fukui, Marie Sarazin, et al.. (2003). Laboratory investigations and treatment in frontotemporal dementia. Annals of Neurology. 54(S5). S32–S35. 18 indexed citations
12.
Grundman, Michael, Clifford R. Jack, Ronald C. Petersen, et al.. (2003). Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. Journal of Molecular Neuroscience. 20(3). 241–248. 59 indexed citations
13.
Mulnard, Ruth A., Carl W. Cotman, Claudia H. Kawas, et al.. (2000). Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. Obstetrical & Gynecological Survey. 439–440. 38 indexed citations
14.
Grundman, Michael, et al.. (1999). Mini-Mental State Examination and Mattis Dementia Rating Scale performance differs in Hispanic and non-Hispanic Alzheimer's disease patients. Journal of the International Neuropsychological Society. 5(4). 301–307. 33 indexed citations
15.
Soliman, Amira & Michael Grundman. (1998). Conservative Management of Colonoscopic Perforation Can Be Misleading. Endoscopy. 30(9). 790–792. 13 indexed citations
16.
Ferris, Steven H., Joan Mackell, Richard C. Mohs, et al.. (1997). A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials. Alzheimer Disease & Associated Disorders. 11. 1–12. 37 indexed citations
17.
Mohs, Richard C., David S. Knopman, Ronald C. Petersen, et al.. (1997). Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs. Alzheimer Disease & Associated Disorders. 11. 13–21. 495 indexed citations
18.
Koss, Elisabeth, Myron Weiner, Christopher Ernesto, et al.. (1997). Assessing Patterns of Agitation in Alzheimerʼs Disease Patients with the Cohen-Mansfield Agitation Inventory. Alzheimer Disease & Associated Disorders. 11. 45–50. 117 indexed citations
19.
Schneider, Lara, Jason T. Olin, Rachelle S. Doody, et al.. (1997). Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Disease & Associated Disorders. 11. 22–32. 528 indexed citations breakdown →
20.
Sano, Mary, Joan Mackell, Marcel O. Pontón, et al.. (1997). The Spanish Instrument Protocol. Alzheimer Disease & Associated Disorders. 11. 57–64. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald G. Thomas Breakdown of academic impact, for papers by Pierre N. Tariot Breakdown of academic impact, for papers by Stephen Salloway Breakdown of academic impact, for papers by Eric Siemers Breakdown of academic impact, for papers by John C.S. Breitner Breakdown of academic impact, for papers by Paul Aisen Breakdown of academic impact, for papers by Lon S. Schneider Breakdown of academic impact, for papers by Francesco Panza Breakdown of academic impact, for papers by Miia Kivipelto Breakdown of academic impact, for papers by Rachelle S. Doody
Rankless by CCL
2026